Last reviewed · How we verify
USEL/Leucovorin
Leucovorin is a folate analog that inhibits the enzyme dihydrofolate reductase, which is involved in DNA synthesis and repair.
Leucovorin is a folate analog that inhibits the enzyme dihydrofolate reductase, which is involved in DNA synthesis and repair. Used for Rescue after high-dose methotrexate therapy, Dihydropyrimidine dehydrogenase deficiency.
At a glance
| Generic name | USEL/Leucovorin |
|---|---|
| Also known as | Leucovorin |
| Sponsor | Hokkaido Gastrointestinal Cancer Study Group |
| Drug class | Antifolate |
| Target | Dihydrofolate reductase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting dihydrofolate reductase, leucovorin reduces the levels of tetrahydrofolate, a necessary cofactor for thymidylate synthase. This action is particularly important in cancer treatment, as it allows for the increased efficacy of 5-fluorouracil, a chemotherapeutic agent that also targets thymidylate synthase.
Approved indications
- Rescue after high-dose methotrexate therapy
- Dihydropyrimidine dehydrogenase deficiency
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |